AVP and metabolic dysfunction-associated steatotic liver disease: In our study, no participant had any clinical or biochemical signs of hepatic damage, making it unlikely that mechanisms involving fluid distribution and vascular compliance underlie the association between high copeptin and NAFLD in our study.